Intra-Cellular Therapies（NASDAQ:ITCI）报告季度每股亏损$(0.16)，未达到分析师一致预期的$(0.11)，差异为45.45%。相比去年同期的每股亏损$(0.29)，这是44.83%的改善。公司报告季度销售额为$1.9922亿，超过分析师一致预期的$1.934亿，超出3.01%。相比去年同期销售额$1.321亿，这是50.81%的增长。

以上内容来自Benzinga Earnings专栏，原文如下：

Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 44.83 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $199.22 million which beat the analyst consensus estimate of $193.40 million by 3.01 percent. This is a 50.81 percent increase over sales of $132.10 million the same period last year.